Decoy Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Decoy Therapeutics Inc. (DCOY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.21% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-31
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.21%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.83%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.89%.
- Decoy Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -6.25%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.21% 10-K · filed 2026-03-31 |
| 2024-12-31 | -0.83% 10-K · filed 2025-03-21 |
| 2023-12-31 | -0.89% 10-K · filed 2025-03-21 |
| 2022-12-31 | -6.25% 10-K · filed 2024-03-22 |
| 2021-12-31 | -0.69% 10-K · filed 2023-03-27 |
| 2020-12-31 | 0.63% 10-K · filed 2022-03-25 |
| 2019-12-31 | -8.69% 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |